Yigal Nochomovitz

Galera Therapeutics Inc (NASDAQ: GRTX), a biopharma company working on novel therapeutics for transforming radiotherapy treatment in cancer, recently IPO'd, offering 5 million shares at $12 apiece. Following the expiry of the IPO quiet period, Citigroup analyst Yigal Nochomovitz initiated...

Mirati Therapeutics Inc (NASDAQ: MRTX)'s shares have been on a tear, advancing over 50 percent since Amgen, Inc. (NASDAQ: AMGN) uploaded an online abstract of its non-small cell lung cancer candidate May 15 to be presented at the ASCO 2019 annual meeting. An analyst at...

The highly volatile biotech stocks present a high-risk-high-reward proposition. Judicious stock picking is essential to ride the superlative rally in some of these stocks in the wake of make-or-break binary events. Here's a brief on a few small-cap biotech stocks Citigroup analyst Yigal...

Translate Bio Inc (NASDAQ: TBIO) went public by offering 9.35 million shares. The offering was priced at $13 per share on June 28. The Analyst With the IPO quiet period expiring, Credit Suisse analyst Yigal Nochomovitz initiated coverage of shares with a Buy rating and a $20 price target. The...

Jefferies and Citigroup initiated coverage for NuCana PLC (ADR) (NASDAQ: NCNA) Monday with a Buy rating and a price target of $25 and $23 respectively. Jefferies' analysts Eun Yang and Carmen Augustine explained that the company is focused on developing safer and more potent chemotherapies for...

Citigroup in a note released Monday, delved into the roadmap for Mirati Therapeutics, Inc. (NASDAQ: MRTX). The firm feels the response for its targeted agent sitravatinib in CBL-mutated non-small cell lung cancer patients puts the company back on targeted therapy map. CBL is a ubiquitin E3 ligase...

Portola Pharmaceuticals Inc (NASDAQ: PTLA) investors should be marking Friday on their calendars. Citi analyst Yigal Nochomovitz expects the Food and Drug Administration to release its decision on betrixaban on Friday, earlier than expected, as it has become a precedent for the FDA to release...

Puma Biotechnology Inc (NASDAQ: PBYI) investors got some major vindication Wednesday when the FDA’s Oncologic Drugs Advisory Committee voted 12–4 to recommend approval of neratinib for treatment of patients with early-stage HER2-positive breast cancer. Puma had plenty of doubters and...

Citi’s Yigal Nochomovitz believes the “opportunity set” for Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)'s pipeline is fully valued in the mid-$60s. Nochomovitz downgraded the rating on the company from Neutral to Sell, while lowering the price target from $66 to $64. MAA...

Long-term investors know the key to success in the stock market is choosing the right stocks and remaining patient. However, some traders prefer more excitement. Here is a look at seven stocks and ETFs that could see major instant upside before the end of the year. 1. Opthotech Corp (NASDAQ: OPHT)...

Ophthotech Corp (NASDAQ: OPHT) has declined 45 percent over the past month, driven by investor concerns regarding the company’s upcoming Phase 3 data. Citi’s Yigal Nochomovitz maintained a Buy rating on the company, with a price target of $92. The Real Story Nochomovitz believes...

Ophthotech Corp (NASDAQ: OPHT), a biopharmaceutical company that develops therapeutics for the treatment of eye diseases, saw its shares fall more than 13 percent Friday. The decline is attributed to an announcement by Regeneron Pharmaceuticals Inc (NASDAQ: REGN), a larger biopharmaceutical...

Portola Pharmaceuticals Inc (NASDAQ: PTLA)'s failure to “proactively mitigate risk with FDA” was the reason for the “surprising” CRL for Andexanet, despite the drug having received breakthrough designation. Citi’s Yigal Nochomovitz downgraded the rating on the company...